A multigene RT-PCR assay used to predict recurrence in early breast cancer: two presentations with contradictory results

被引：2

作者：

Fiets, WE ^{[1
]}

Nortier, JWR ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Med Oncol, NL-2300 RA Leiden, Netherlands

来源：

BREAST CANCER RESEARCH | 2004年 / 6卷 / 05期

关键词：

breast cancer; predictive marker; prognostic marker; RNA;

D O I：

10.1186/bcr911

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

During the 2003 San Antonio Breast Cancer Symposium two studies were presented that were designed to validate a recurrence score, derived from a 21-gene RT-PCR assay, in patients with axillary node-negative breast cancer. This recurrence score was highly predictive for the risk of recurrence in 668 patients treated in a large multicenter trial with adjuvant tamoxifen. However, no prognostic value was found in a small group of patients who were retrospectively selected in a single institution and who did not receive any adjuvant systemic therapy. Further validation is needed to establish the prognostic and predictive role of this assay in clinical management.

引用

页码：185 / 187

页数：3

共 15 条

[1]

[Anonymous], P AM SOC CLIN ONCOL

[2] Cancer - The molecular outlook [J].

Caldas, C ;

Aparicio, SAJ .

NATURE, 2002, 415 (6871) :484-485

[3] c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases [J].

Carlomagno, C ;

Perrone, F ;

Gallo, C ;

DeLaurentiis, M ;

Lauria, R ;

Morabito, A ;

Pettinato, G ;

Panico, L ;

DAntonio, A ;

Bianco, AR ;

DePlacido, S .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2702-2708

[4]

Cobleigh MA, 2003, P AN M AM SOC CLIN, V22, pA3415

[5] Measurement of gene expression in archival paraffin-embedded tissues - Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay [J].

Cronin, M ;

Pho, M ;

Dutta, D ;

Stephans, JC ;

Shak, S ;

Kiefer, MC ;

Esteban, JM ;

Baker, JB .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :35-42

[6] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].

Ellis, MJ ;

Coop, A ;

Singh, B ;

Mauriac, L ;

Llombert-Cussac, A ;

Jänicke, F ;

Miller, WR ;

Evans, DB ;

Dugan, M ;

Brady, C ;

Quebe-Fehling, E ;

Borgs, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816

[7]

Esteva FJ, 2003, BREAST CANCER RES TR, V82, pS11

[8] Meeting highlights:: Updated international expert consensus on the primary therapy of early breast cancer [J].

Goldhirsch, A ;

Wood, WC ;

Gelber, RD ;

Coates, AS ;

Thürlimann, B ;

Senn, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3357-3365

[9] New prognostic factors for breast cancer recurrence [J].

Isaacs, C ;

Stearns, V ;

Hayes, DF .

SEMINARS IN ONCOLOGY, 2001, 28 (01) :53-67

[10]

Lewis F, 2001, J PATHOL, V195, P66, DOI 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO

← 1 2 →